Rami Komrokji, M.D.

After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Rami Komrokji completed an internship and residency at Case Western University, St. Vincent Program.  He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.

Dr Komrokji is expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and for Pacritinib in myelofibrosis.

He has authored or co-authored more than 350 peer-reviewed manuscripts, 20 book chapters, and more than 1000 abstracts in Hematologic Malignancies. He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and currently member of the NHLBI MDS natural history study steering committee and aplastic anemia and MDS foundation medical board of directors.

Dr. Komrokji’s research interests are in Phase I and II Clinical Trials, and in the outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Myeloid Leukemias, and Myeloproliferative neoplasms.